Pharmaceutical

Bayer launches respiratory awareness contest

Bayer launches respiratory awareness contest

By

Encouraging competitors to take an artistic approach to "Breathless Moments," the competition is a first for Bayer, which is already working on next year's effort.

Valeant adds to dermatology portfolio

Onexton is a first-and-only drug combination for treating acne.

Bayer looks to exit diabetes device business

The German firm positions to focus on pharma pipeline and animal health.

Five things for pharma marketers to know: Tuesday, November 25

Five things for pharma marketers to know: Tuesday, November 25

By By

AstraZeneca and Ranbaxy pay-for-delay case marches on; FDA extends Novartis multiple myeloma Priority Review timeline; Endo pays $25 for testosterone nasal gel.

FDA tempers opioid approval impact

FDA tempers opioid approval impact

By

The Center for Drug Evaluation and Research's director says there is a need for new opioids and cuts off dosing comparisons between extended-release and immediate-release opioids.

India to reorg pharmaceutical agencies

The reason: coordination and effectiveness.

Five things for pharma marketers to know: Monday, November 24

Five things for pharma marketers to know: Monday, November 24

By

BioMarin to acquire Dutch biotech Prosensa; Woodcock says significant efficacy key to Breakthrough Therapy designation; Stryker considers $16 billion bid for UK devicemaker Smith and Nephew.

Five things for pharma marketers to know: Friday, November 21

Five things for pharma marketers to know: Friday, November 21

By By By

EMA revises its conflict of interest policy; AbbVie all-oral HCV combo drug receives positive EU recommendation; Merck may help NewLink Genetics scale production of its Ebola vaccine.

Sanofi offers glimpse of next-gen. insulin strategy

Sanofi offers glimpse of next-gen. insulin strategy

By

In a company-hosted seminar today, the Paris-based drugmaker gave investors a preview of the future of its diabetes franchise.

World projected to spend $1T on drugs in 2018

World projected to spend $1T on drugs in 2018

By

The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.

Gilead buys priority voucher for $125M

The scoop means the maker of HCV drugs Harvoni and Sovaldi can give any drug an accelerated review time.

Five things for pharma marketers to know: Wednesday, November 19

Five things for pharma marketers to know: Wednesday, November 19

By

Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.

Analyses support Pradaxa safety profile

Analyses support Pradaxa safety profile

By

Results of two post-market studies, conducted in part by Boehringer Ingelheim, corroborate the billion-dollar blood thinner's benefit/risk profile.

PCSK9s stalk Merck's Vytorin

PCSK9s stalk Merck's Vytorin

By

A head-to-head comparison between Sanofi and Regeneron's experimental PCSK9 shows alirocumab lowers LDL levels more effectively than Merck's Zetia, which is part of the just-acquitted Vytorin.

Tufts: drug dev costs have jumped 145%

Tufts: drug dev costs have jumped 145%

By

Researchers say the average cost of bringing a drug from concept to approval, and through post-approval assessments for reasons such as new doses or formulations, hovers at around $2.8 billion per drug in 2013 dollars.

Study finds new benefits in highly promising heart drug

A pipeline drug from Novartis has the potential to alter the progression of heart disease and keep patients out of the hospital.

Five things for pharma marketers to know: Tuesday, November 18

Five things for pharma marketers to know: Tuesday, November 18

By By

Ackman walks away with $2.5 billion, despite no Allergan deal; Ranbaxy sues FDA over generic Nexium rights; Indian government's Health Ministry recommends breaking BMS cancer drug patent.

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

Merck's IMPROVE-IT trial hits big, supports wider Zetia use

By

Patients taking Vytorin experienced a 6.4% reduced relative risk for cardiovascular events, the company said.

Five things for pharma marketers to know: Monday, November 17

Five things for pharma marketers to know: Monday, November 17

By

Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.

Five things for pharma marketers to know: Friday, November 14

Five things for pharma marketers to know: Friday, November 14

By By

Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.

BMS striving to push Opdivo past Keytruda

BMS striving to push Opdivo past Keytruda

By

Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with the competition, according to one analyst.

IMS predicts $1T global drug market by 2017

IMS predicts $1T global drug market by 2017

By

The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.

New York Magazine examines cancer drug pricing

New York Magazine examines cancer drug pricing

A wide-ranging piece recounts the pushback from oncologists that led to a decrease in the price of Zaltrap.

GSK breaks cloud cover with financial results

GSK breaks cloud cover with financial results

By

GlaxoSmithKline second-quarter sales rose 2% over the same period last year. CEO Andrew Witty says it is too early to tally the impact of China's corruption allegations.

Business briefs: GSK and Sanofi, plus state legislative news

GlaxoSmithKline says it is scaling back on acquisitions; Sanofi's CEO picks a regulatory fight; Maine wants to allow Ex-US meds; and New York State seeks to empower pharmacists.

J&J OTC sales slipped 3% in 2012 worldwide

By

CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year's numbers.

Branded drug spend up, but slower growth ahead

By

Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.

Company news: GlaxoSmithKline, AstraZeneca, Nature Publishing

GlaxoSmithKline is building its first new UK factory in almost 40 years, the firm said, spurring jobs while breaking new ground at some of its current locations.

As brand revenue shrinks, so does brand promotion

By

Branded drug sales declined 0.7% to $229 billion last year, according to IMS Health, and that's having an impact on promotional spend.

Which Pfizer brands could stay, go in a sell-off

Which Pfizer brands could stay, go in a sell-off

By

Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters